EMA
- Application: EMEA/H/C/000609
- Local brand name: Kepivance
- Status: withdrawn
Kepivance (PALIFERMIN) regulatory status in European Union.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA has authorised it.
Biovitrum Ab is the originator. The local marketing authorisation holder may differ — check the official source linked above.